Unnatural Products utilizes an AI-enhanced discovery platform to engineer synthetic macrocycles that mimic natural macrocycles, enabling targeted therapies for complex drug targets that are typically undruggable by small molecules or biologics. This approach addresses the limitations of existing drug modalities by providing a new class of therapeutics with improved cell permeability and oral bioavailability.
Funding
$38.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AV+1Founders
Product
Problem
Many complex drug targets are considered "undruggable" by traditional small molecules due to their inability to bind effectively, while biologics are limited by their inability to permeate cell membranes and act on intracellular targets. This leaves a significant portion of potential drug targets inaccessible, hindering the development of effective therapies for various diseases.
Solution
Unnatural Products is developing a novel class of therapeutics based on synthetic macrocycles, designed to mimic the properties of natural macrocycles. Their AI-enhanced discovery platform engineers these synthetic macrocycles to address complex drug targets that are typically beyond the reach of small molecules or biologics. These macrocycles are designed to combine the cell permeability and oral bioavailability of small molecules with the target specificity of biologics, enabling them to engage intracellular targets with high affinity and potentially leading to orally delivered therapeutics for previously undruggable targets. The platform leverages insights from natural macrocycles to intelligently design, rapidly synthesize, and screen cyclic peptide macrocycles.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking novel therapeutic modalities to address challenging drug targets and develop innovative treatments for diseases currently lacking effective therapies.
Features
- AI-enhanced discovery platform for designing synthetic macrocycles that mimic natural macrocycles.
- Technology to intelligently design, rapidly synthesize, and screen cyclic peptide macrocycles.
- Macrocycles designed for improved cell permeability and oral bioavailability compared to biologics.
- Ability to engage complex and intracellular drug targets inaccessible to traditional small molecules.
- Potential for orally delivered therapeutics for previously undruggable targets.